Ovid Therapeutics (OVID)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	16.95 mm	16.95 mm	16.95 mm	16.95 mm	16.95 mm	16.95 mm
Cash burn (monthly)	4.89 mm	3.53 mm	4.67 mm	5.84 mm	5.00 mm	4.82 mm
Cash used (since last report)	25.92 mm	18.73 mm	24.73 mm	30.96 mm	26.50 mm	25.54 mm
Cash remaining	-8.97 mm	-1.78 mm	-7.78 mm	-14.01 mm	-9.55 mm	-8.59 mm
Runway (months of cash)	-1.8	-0.5	-1.7	-2.4	-1.9	-1.8

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

OVID institutional ownership history Ownership history

68.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	77	76	+1.3%
Opened positions	10	15	-33.3%
Closed positions	9	19	-52.6%
Increased positions	31	23	+34.8%
Reduced positions	16	24	-33.3%

13F shares	Current	Prev Q	Change
Total value	42.24 bn	27.33 bn	+54.5%
Total shares	48.73 mm	51.43 mm	-5.2%
Total puts	500.00	200.00	+150.0%
Total calls	37.40 k	10.30 k	+263.1%
Total put/call ratio	0.0	0.0	-31.1%

Largest owners	Shares	Value	Change
EcoR1 Capital Fund	6.08 mm	$24.45 mm	0.0%
Rubric Capital Management	5.32 mm	$6.27 bn	0.0%
BlackRock	4.31 mm	$5.09 bn	NEW
Madison Avenue Partners	4.12 mm	$4.86 bn	+0.8%
Biotechnology Value Fund L P	3.85 mm	$4.43 mm	-43.7%
BVF	3.85 mm	$4.55 bn	0.0%
Vanguard	3.14 mm	$3.71 bn	+1.7%
Siren, L.L.C.	2.85 mm	$3.36 bn	NEW
Acadian Asset Management	1.85 mm	$2.18 mm	+11.0%
Kennedy Capital Management	1.53 mm	$1.80 bn	+2.6%

Largest transactions	Shares	Bought/sold	Change
BlackRock	4.31 mm	+4.31 mm	NEW
BLK BlackRock	0.00	-3.99 mm	EXIT
Biotechnology Value Fund L P	3.85 mm	-3.00 mm	-43.7%
Siren, L.L.C.	2.85 mm	+2.85 mm	NEW
Artal	0.00	-2.50 mm	EXIT
FFT Wealth Management	0.00	-489.55 k	EXIT
TLS Advisors	771.53 k	-353.77 k	-31.4%
Prosight Management	729.21 k	-345.79 k	-32.2%
Ubs Oconnor	628.29 k	+340.00 k	+117.9%
BNP Paribas Arbitrage	220.40 k	+215.19 k	+4128.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

OVID insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
3 Mar 25	Papadopoulos Stelios	Stock Option Common Stock	Grant	Acquire A	No	No	0.49	90,000	44.10 k	90,000
26 Feb 25	Margaret A. Alexander	Common Stock	Sell	Dispose S	No	No	0.56	5,279	2.96 k	73,406
26 Feb 25	Jeffrey A Rona	Common Stock	Sell	Dispose S	No	No	0.56	3,902	2.19 k	67,973
20 Feb 25	Jeremy M Levin	Employee Stock Option Common Stock	Grant	Acquire A	No	No	0.57	1,650,000	940.50 k	1,650,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Oppenheimer Upgrades Ovid Therapeutics to Outperform, Announces $4 Price Target

29 Jan 25

Oppenheimer analyst Francois Brisebois upgrades Ovid Therapeutics (NASDAQ:OVID) from Perform to Outperform and announces $4 price target.

Press releases

From Benzinga Pro

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

5 Feb 25

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that